Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $123.9 million.

  • Immunome's Cash from Investing Activities rose 414.08% to $123.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.6 million, marking a year-over-year increase of 159.73%. This contributed to the annual value of -$85.1 million for FY2024, which is 179.04% down from last year.
  • As of Q3 2025, Immunome's Cash from Investing Activities stood at $123.9 million, which was up 293.05% from -$64.2 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Cash from Investing Activities registered a high of $123.9 million during Q3 2025, and its lowest value of -$81.7 million during Q2 2024.
  • In the last 3 years, Immunome's Cash from Investing Activities had a median value of -$106,000 in 2023 and averaged -$4.6 million.
  • Over the last 5 years, Immunome's Cash from Investing Activities had its largest YoY gain of 67,038.89% in 2024, and its largest YoY loss of 35,023.58% in 2024.
  • Quarterly analysis of 3 years shows Immunome's Cash from Investing Activities stood at -$30.0 million in 2023, then surged by 132.52% to $9.8 million in 2024, then skyrocketed by 414.08% to $123.9 million in 2025.
  • Its Cash from Investing Activities stands at $123.9 million for Q3 2025, versus -$64.2 million for Q2 2025 and $5.1 million for Q1 2025.